Sanofi SA vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Vanguard Total Stock Market Index Fund ETF trades at $381.94 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 24.2× Sanofi SA's market cap, and Sanofi SA pays a 6.01% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| SNY | VTI | |
|---|---|---|
Market Cap | $95.18B | $2.30T |
Volume | 2,995,646 | 2,982,924 |
Sector | Health | — |
52-Week High | $52.34 | $384.30 |
52-Week Low | $39.51 | $311.68 |
Typical Hold Time | 94 Days | 131 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
VTI trades at $381.94, up 0.24% on the day, with a bullish technical signal from moving averages. The ETF offers broad exposure to the U.S. stock market, though key valuation ratios like P/E and P/S are not provided in the current data. Recent news highlights its role in diversified portfolios and long-term growth potential, with a dividend scheduled for late September 2026.
The outlook for VTI is supported by its low-cost, diversified structure, appealing to long-term investors. Risks include market concentration in top holdings and overall equity market volatility. Analyst sentiment is generally positive, emphasizing its suitability for retirement and growth strategies amid current economic conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →